Thank you!

To all our local organizers, IMS leadership, faculty, presenters, attendees, and sponsors, thank you for making the 17th International Myeloma Workshop (IMW) a great success!

Over 3200 registered delegates attended the 17th IMW, the largest in the history of the workshop. In addition to 150 invited faculty, over 600 study abstracts were presented at the 17th IMW in oral and poster sessions, including 150 from young investigators.

Congratulations to the 40 young investigators who were honored at the 17th IMW, and to Professor Giampaolo Merlini who received the Jan Gosta Waldenstrom Award for lifetime contributions to myeloma; Dr. Constantine Mitisades who received the Kenneth C. Anderson Young Investigator Award for Basic and Translational Research; and Dr. Francesca Gay who received the Bart Barlogie Young Investigator Award for Therapeutics.

The 18th IMW will be held September 8-11, 2021, in Vienna, Austria under the auspices of professors Heinz Ludwig, Hermann Einsele, Hartmut Goldschmidt and Roman Hajek. More information on the 18th IMW will be forthcoming at

Steve Treon, Paul Richardson, Ken Anderson, Nikhil Munshi
and all the organizers of the 17th IMW

Attendee Registration - 7:00 am to 1:00 pm

Sunday, September 15, 2019


Plenary Session


Scheduled Time

Plenary Session: Late Breaking Abstracts    
Session Chairs F Gay/N van de Donk  
AB900 Circulating Tumor Cells for Comprehensive and Multiregional Non Invasive Genetic Characterization of MM  J Garces  8:00 AM
AB908 Single Cell Characterization of MM Immune Micorenvironment Identifies CD-27-Negative T Cells as Potential Tumor Reactive Lymphocytes  C Botta  8:15 AM
AB904 Melflufen in Relapsed/Refractory MM in Phase 2 Horizon Study: Promising Results in High Risk Population  P Richardson  8:30 AM
AB906 Daratumamab, Lenalidomide, Bortezomib and Dex Improves Depth of Response in Transplant Eligible Newly Diagnosed MM: Griffin Study  P Voorhees   8:45 AM
Great Debates in Myeloma    
Moderators V Rajkumar/MV Mateos  
Should we treat smoldering myeloma? I Ghobrial (Yes) /A Dispenzieri(No) 9:00 AM
Should RVD/KRD be considered the standard frontline induction regimen? P Richardson (RVD) / K Stewart (KRD) 9:20 AM
Should MRD negativity be the end point of therapy? J San Miguel (Yes) / S Jagannath (No) 9:40 AM
Is definitive duration or indefinite lenalidomide the right choice for maintenance? P Moreau (Definitive) / P McCarthy (Indefinite) 10:00 AM
Should monoclonal antibodies be included for induction in every MM patient? S Kastritis (Yes) / P Voorhees (No) 10:20 AM
Will ASCT remain a standard of care in 5 years? P Sonneveld (Yes) / O Landgren (No) 10:40 AM
Clinical Trials in Progress    
Moderators D Reece/T Martin  
North America  S Kumar/R Orlowski 11:00 AM
Europe  S Zweegman/T Facon 11:20 AM
South America  V Hungria 11:40 AM
Asia  L Qui/K Shimizu 12:00 PM
Australia  A Spencer/ J Ho 12:20 PM
Closing Comments Organizers of IMW17 12:40 PM
Welcome to IMW18 Organizers of IMW18  12:50 PM
Program Adjournment   1:00 PM

Important Information for Speakers and Presenters 


Workshop Organizers

Christopher Patterson
IMW 17 Secretariat

Dana Farber Cancer Institute
Mayor 548
450 Brookline Avenue
Boston, MA 02215
+1 617 632 6285


Follow the IMS

icon facebook icon twitter

Become a Member Today

Housing & Registration


c/o SPARGO, Inc.
11208 Waples Mill Road
Suite 112
Fairfax, VA 22030 USA
888-788-1522 (US Toll free)
+ 1 703-449-6418 (International)

Reserve Now

Contact the IMS

International Myeloma Society

Lisa Sikkink, IMS Assistant

International Myeloma Society
Mayo Clinic
Siebens 6-60
200 First Street SW
Rochester, MN 55905
+1 507 284 3725